CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. The company's product candidate in pipeline includes tosedostat, a novel oral, once-daily aminopeptidase inhibitor for patients with acute myeloid leukemia. It has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; Teva Pharmaceutical Industries Ltd; University of Vermont; S*BIO Pte Ltd; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTIC
CUSIPN/A
Phone206-282-7100
Debt
Debt-to-Equity Ratio0.17
Current Ratio5.32
Quick Ratio5.30
Price-To-Earnings
Trailing P/E Ratio-4.07
Forward P/E Ratio-5.32
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.15 million
Price / Sales11.64
Cash FlowN/A
Price / CashN/A
Book Value$0.35 per share
Price / Book14.43
Profitability
EPS (Most Recent Fiscal Year)($1.24)
Net Income$-40,670,000.00
Net Margins-71.30%
Return on Equity-63.27%
Return on Assets-30.84%
Miscellaneous
Employees57
Outstanding Shares57,980,000
CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions
What is CTI BioPharma's stock symbol?
CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."
When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?
CTI BioPharma's stock reverse split on Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.
How were CTI BioPharma's earnings last quarter?
CTI BioPharma Corp (NASDAQ:CTIC) announced its quarterly earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02. The biopharmaceutical company had revenue of $10.48 million for the quarter, compared to the consensus estimate of $10.30 million. CTI BioPharma had a negative net margin of 71.30% and a negative return on equity of 63.27%. View CTI BioPharma's Earnings History.
When is CTI BioPharma's next earnings date?
What price target have analysts set for CTIC?
5 brokers have issued twelve-month price objectives for CTI BioPharma's stock. Their forecasts range from $5.00 to $10.00. On average, they expect CTI BioPharma's stock price to reach $7.10 in the next twelve months. View Analyst Ratings for CTI BioPharma.
What are Wall Street analysts saying about CTI BioPharma stock?
Here are some recent quotes from research analysts about CTI BioPharma stock:
- 1. According to Zacks Investment Research, "CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington. " (4/25/2018)
- 2. Cann analysts commented, "CTI BioPharma released Q4 2017 results today with lower-than-expected sales and slightly higher-than-estimated SG&A. Total revenue of $462,000 was lower than our estimated $1.7 million. All revenue was from License and Contract Revenue. Total operating expenses of $14.2 million were 6.3% higher than our estimated $13.3 million due to higher-than-estimated SG&A expense. CTI BioPharma lost $0.33 per share compared to our estimated loss per share of $0.28. Our 2018–2024 outlook is basically unchanged for CTI BioPharma. Programs are advancing, with data expected in H1 2018." (3/7/2018)
Who are some of CTI BioPharma's key competitors?
Some companies that are related to CTI BioPharma include Revance Therapeutics (RVNC), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), Eagle Pharmaceuticals (EGRX), Esperion Therapeutics (ESPR), TG Therapeutics Inc common stock (TGTX), Epizyme (EPZM), Reata Pharmaceuticals (RETA), Dynavax Technologies (DVAX), Endocyte (ECYT), Flexion Therapeutics (FLXN), Vanda Pharmaceuticals (VNDA), CytomX Therapeutics (CTMX), Arrowhead Pharmaceuticals (ARWR) and Assembly Biosciences (ASMB).
Who are CTI BioPharma's key executives?
CTI BioPharma's management team includes the folowing people:
- Dr. Adam R. Craig, Pres, CEO & Director (Age 52)
- Dr. Jack W. Singer, Co-Founder, Exec. VP, Chief Scientific Officer, Interim CMO & Global Head-Translational Medicine (Age 75)
- Mr. David H. Kirske, Exec. VP & CFO (Age 64)
- Mr. Bruce J. Seeley, COO, Exec. VP & Sec. (Age 54)
- Mr. Ed Bell, Sr. Director of Investor Relations
Has CTI BioPharma been receiving favorable news coverage?
Media headlines about CTIC stock have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CTI BioPharma earned a coverage optimism score of 0.16 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 43.76 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are CTI BioPharma's major shareholders?
CTI BioPharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (11.95%), NEA Management Company LLC (6.47%), Franklin Resources Inc. (5.99%), Millennium Management LLC (1.36%), BlackRock Inc. (0.75%) and JPMorgan Chase & Co. (0.46%). Company insiders that own CTI BioPharma stock include Bvf Partners L P/Il, James A Bianco, Richard L Love and Value Fund L P Biotechnology. View Institutional Ownership Trends for CTI BioPharma.
Which major investors are selling CTI BioPharma stock?
Which major investors are buying CTI BioPharma stock?
CTIC stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC, Franklin Resources Inc., Millennium Management LLC, JPMorgan Chase & Co., Tibra Equities Europe Ltd, Northern Trust Corp, Element Capital Management LLC and Barclays PLC. Company insiders that have bought CTI BioPharma stock in the last two years include Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for CTI BioPharma.
How do I buy shares of CTI BioPharma?
Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CTI BioPharma's stock price today?
One share of CTIC stock can currently be purchased for approximately $5.05.
How big of a company is CTI BioPharma?
CTI BioPharma has a market capitalization of $295.68 million and generates $25.15 million in revenue each year. The biopharmaceutical company earns $-40,670,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. CTI BioPharma employs 57 workers across the globe.
How can I contact CTI BioPharma?
CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]
MarketBeat Community Rating for CTI BioPharma (CTIC)
MarketBeat's community ratings are surveys of what our community members think about CTI BioPharma and other stocks. Vote "Outperform" if you believe CTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
